首页> 外文期刊>Genetics in medicine >SLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy
【24h】

SLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy

机译:SLC39A8缺乏:生物化学修正和锰治疗的主要临床改善

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: SLC39A8 deficiency is a severe inborn error of metabolism that is caused by impaired function of manganese metabolism in humans. Mutations in SLC39A8 lead to impaired function of the manganese transporter ZIP8 and thus manganese deficiency. Due to the important role of Mn2+ as a cofactor for a variety of enzymes, the resulting phenotype is complex and severe. The manganese-dependence of beta-1,4-galactosyltransferases leads to secondary hypoglycosylation, making SLC39A8 deficiency both a disorder of trace element metabolism and a congenital disorder of glycosylation. Some hypoglycosylation disorders have previously been treated with galactose administration. The development of an effective treatment of the disorder by high-dose manganese substitution aims at correcting biochemical, and hopefully, clinical abnormalities.
机译:目的:SLC39A8缺乏是代谢的严重天生的误差,这是由人类代谢的失效引起的。 SLC39A8中的突变导致锰转运蛋白ZIP8的功能受损,因此锰缺乏症。 由于Mn2 +作为各种酶的辅助因子的重要作用,所得表型是复杂和严重的。 β-1,4-半乳糖基转移酶的锰依赖性导致二级低糖基化,使SLC39A8缺乏缺乏痕量元素代谢和先天性糖基化疾病。 先前已经用半乳糖给药治疗了一些低糖基化疾病。 通过高剂量锰取代的有效治疗病症的有效治疗旨在纠正生化,希望临床异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号